Radiotherapy for isolated lymph node metastases in patients with locally advanced prostate cancer after primary therapy

Christoph Henkenberens, Axel S. Merseburger, Frank Bengel, Thorsten Derlin, Katja Hueper, Viktor Grünwald, Hans Christiansen

Research output: Contribution to journalArticle

Abstract

Purpose: To evaluate the outcome of radiotherapy for isolated lymph node metastases in patients with progression towards castration-resistant prostate cancer (CRPC) after definitive therapy. Methods: Between 11/2009 and 06/2014, 18 patients with isolated lymph node metastases after definitive prostate cancer therapy received radiotherapy to the affected lymph nodes with a total dose of 50.4 or 54.0 Gray (Gy). All patients had continuously rising levels of PSA despite androgen deprivation therapy (ADT). Biochemical progression-free survival (BPFS), clinical failure-free survival (CFFS) and freedom from local failure were assessed, as was the toxicity profile. Results: Of the 18 patients, 17 had high-risk prostate cancer. Radiotherapy was performed at a median interval of 64.55 [interquartile range (IQR) 23.2–153.8] months after definitive therapy. ADT was administered for a median (IQR) time of 3.8 (3.2–24.7) months prior to irradiation. The median (IQR) follow-up was 15.59 (5.3–28.5) months with 94.1 % freedom from local failure. The median BPFS and CFFS were 5.85 (IQR 3.0–20.3) and 9.60 months (IQR 5.9–28.8), respectively. No grade III acute or grade II late toxicity was observed. Only two patients developed local relapse. No patients exhibited deterioration of urinary or faecal continence. Conclusion: Radiotherapy of isolated lymph node metastases in patients who develop CRPC provides effective local control, is not associated with clinically important acute or long-term side effects, improves PSA kinetics and may delay the necessity of chemotherapy.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalWorld Journal of Urology
DOIs
StateAccepted/In press - Nov 27 2015
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Radiotherapy
Lymph Nodes
Neoplasm Metastasis
Castration
Therapeutics
Androgens
Disease-Free Survival
Survival
Recurrence
Drug Therapy

Keywords

  • Local control
  • Lymph node metastases
  • Radiotherapy
  • Recurrence prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Henkenberens, C., Merseburger, A. S., Bengel, F., Derlin, T., Hueper, K., Grünwald, V., & Christiansen, H. (Accepted/In press). Radiotherapy for isolated lymph node metastases in patients with locally advanced prostate cancer after primary therapy. World Journal of Urology, 1-7. https://doi.org/10.1007/s00345-015-1733-y

Radiotherapy for isolated lymph node metastases in patients with locally advanced prostate cancer after primary therapy. / Henkenberens, Christoph; Merseburger, Axel S.; Bengel, Frank; Derlin, Thorsten; Hueper, Katja; Grünwald, Viktor; Christiansen, Hans.

In: World Journal of Urology, 27.11.2015, p. 1-7.

Research output: Contribution to journalArticle

Henkenberens, Christoph ; Merseburger, Axel S. ; Bengel, Frank ; Derlin, Thorsten ; Hueper, Katja ; Grünwald, Viktor ; Christiansen, Hans. / Radiotherapy for isolated lymph node metastases in patients with locally advanced prostate cancer after primary therapy. In: World Journal of Urology. 2015 ; pp. 1-7.
@article{3be2412ccfa247f09e49c0bd7f03f150,
title = "Radiotherapy for isolated lymph node metastases in patients with locally advanced prostate cancer after primary therapy",
abstract = "Purpose: To evaluate the outcome of radiotherapy for isolated lymph node metastases in patients with progression towards castration-resistant prostate cancer (CRPC) after definitive therapy. Methods: Between 11/2009 and 06/2014, 18 patients with isolated lymph node metastases after definitive prostate cancer therapy received radiotherapy to the affected lymph nodes with a total dose of 50.4 or 54.0 Gray (Gy). All patients had continuously rising levels of PSA despite androgen deprivation therapy (ADT). Biochemical progression-free survival (BPFS), clinical failure-free survival (CFFS) and freedom from local failure were assessed, as was the toxicity profile. Results: Of the 18 patients, 17 had high-risk prostate cancer. Radiotherapy was performed at a median interval of 64.55 [interquartile range (IQR) 23.2–153.8] months after definitive therapy. ADT was administered for a median (IQR) time of 3.8 (3.2–24.7) months prior to irradiation. The median (IQR) follow-up was 15.59 (5.3–28.5) months with 94.1 {\%} freedom from local failure. The median BPFS and CFFS were 5.85 (IQR 3.0–20.3) and 9.60 months (IQR 5.9–28.8), respectively. No grade III acute or grade II late toxicity was observed. Only two patients developed local relapse. No patients exhibited deterioration of urinary or faecal continence. Conclusion: Radiotherapy of isolated lymph node metastases in patients who develop CRPC provides effective local control, is not associated with clinically important acute or long-term side effects, improves PSA kinetics and may delay the necessity of chemotherapy.",
keywords = "Local control, Lymph node metastases, Radiotherapy, Recurrence prostate cancer",
author = "Christoph Henkenberens and Merseburger, {Axel S.} and Frank Bengel and Thorsten Derlin and Katja Hueper and Viktor Gr{\"u}nwald and Hans Christiansen",
year = "2015",
month = "11",
day = "27",
doi = "10.1007/s00345-015-1733-y",
language = "English (US)",
pages = "1--7",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Radiotherapy for isolated lymph node metastases in patients with locally advanced prostate cancer after primary therapy

AU - Henkenberens, Christoph

AU - Merseburger, Axel S.

AU - Bengel, Frank

AU - Derlin, Thorsten

AU - Hueper, Katja

AU - Grünwald, Viktor

AU - Christiansen, Hans

PY - 2015/11/27

Y1 - 2015/11/27

N2 - Purpose: To evaluate the outcome of radiotherapy for isolated lymph node metastases in patients with progression towards castration-resistant prostate cancer (CRPC) after definitive therapy. Methods: Between 11/2009 and 06/2014, 18 patients with isolated lymph node metastases after definitive prostate cancer therapy received radiotherapy to the affected lymph nodes with a total dose of 50.4 or 54.0 Gray (Gy). All patients had continuously rising levels of PSA despite androgen deprivation therapy (ADT). Biochemical progression-free survival (BPFS), clinical failure-free survival (CFFS) and freedom from local failure were assessed, as was the toxicity profile. Results: Of the 18 patients, 17 had high-risk prostate cancer. Radiotherapy was performed at a median interval of 64.55 [interquartile range (IQR) 23.2–153.8] months after definitive therapy. ADT was administered for a median (IQR) time of 3.8 (3.2–24.7) months prior to irradiation. The median (IQR) follow-up was 15.59 (5.3–28.5) months with 94.1 % freedom from local failure. The median BPFS and CFFS were 5.85 (IQR 3.0–20.3) and 9.60 months (IQR 5.9–28.8), respectively. No grade III acute or grade II late toxicity was observed. Only two patients developed local relapse. No patients exhibited deterioration of urinary or faecal continence. Conclusion: Radiotherapy of isolated lymph node metastases in patients who develop CRPC provides effective local control, is not associated with clinically important acute or long-term side effects, improves PSA kinetics and may delay the necessity of chemotherapy.

AB - Purpose: To evaluate the outcome of radiotherapy for isolated lymph node metastases in patients with progression towards castration-resistant prostate cancer (CRPC) after definitive therapy. Methods: Between 11/2009 and 06/2014, 18 patients with isolated lymph node metastases after definitive prostate cancer therapy received radiotherapy to the affected lymph nodes with a total dose of 50.4 or 54.0 Gray (Gy). All patients had continuously rising levels of PSA despite androgen deprivation therapy (ADT). Biochemical progression-free survival (BPFS), clinical failure-free survival (CFFS) and freedom from local failure were assessed, as was the toxicity profile. Results: Of the 18 patients, 17 had high-risk prostate cancer. Radiotherapy was performed at a median interval of 64.55 [interquartile range (IQR) 23.2–153.8] months after definitive therapy. ADT was administered for a median (IQR) time of 3.8 (3.2–24.7) months prior to irradiation. The median (IQR) follow-up was 15.59 (5.3–28.5) months with 94.1 % freedom from local failure. The median BPFS and CFFS were 5.85 (IQR 3.0–20.3) and 9.60 months (IQR 5.9–28.8), respectively. No grade III acute or grade II late toxicity was observed. Only two patients developed local relapse. No patients exhibited deterioration of urinary or faecal continence. Conclusion: Radiotherapy of isolated lymph node metastases in patients who develop CRPC provides effective local control, is not associated with clinically important acute or long-term side effects, improves PSA kinetics and may delay the necessity of chemotherapy.

KW - Local control

KW - Lymph node metastases

KW - Radiotherapy

KW - Recurrence prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84948422911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948422911&partnerID=8YFLogxK

U2 - 10.1007/s00345-015-1733-y

DO - 10.1007/s00345-015-1733-y

M3 - Article

SP - 1

EP - 7

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

ER -